NCT04502901View on ClinicalTrials.gov

the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

August 11, 2020

Study Completion Date

January 15, 2021

Conditions
Androgenetic Alopecia
Interventions
DRUG

KX0826

investigational AR antagonist

OTHER

Placebo

Placebo of KX-826

Trial Locations (1)

33136

inVentiv Health Clinical Research Services LLC, Miami

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT04502901 - the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending | Biotech Hunter | Biotech Hunter